Microba Life Sciences
Melbourne, Australia· Est.
Clinical‑grade, multi‑omics microbiome testing delivering actionable, evidence‑backed health insights.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Clinical‑grade, multi‑omics microbiome testing delivering actionable, evidence‑backed health insights.
GastrointestinalMetabolicImmunology
Technology Platform
Multi‑omics microbiome profiling that integrates shotgun metagenomics, targeted PCR, and ELISA‑based GI markers within an ISO15189‑accredited laboratory, paired with a bioinformatics engine linking results to >1,500 peer‑reviewed studies.
Opportunities
Expansion into US and European markets, integration with pharma clinical trials for microbiome‑targeted therapies, and development of longitudinal health monitoring services.
Risk Factors
Regulatory uncertainty for microbiome diagnostics, data privacy concerns, and competition from well‑funded consumer‑focused microbiome testing companies.
Competitive Landscape
Competes with Viome, DayTwo, Thryve, and other microbiome testing firms; Microba differentiates through clinical‑grade validation, multi‑omics integration, and evidence‑backed actionable insights.